Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study

Gynecologic Oncology

Volumn 129, Issue 2, 2013, Pages 310-317

  Jordan, S ^a   Steer, C ^b   DeFazio, A ^c   Quinn, M ^d   Obermair, A ^e   Friedlander, M ^f   Francis, J ^g   O'Brien, S ^a   Goss, G ^h   Wyld, D ^e   Webb, P ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Border Medical Oncology Australia   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f PRINCE OF WALES HOSPITAL   (Australia)

^g Cancer Australia   (Australia)

^h BOX HILL HOSPITAL   (Australia)

Author keywords

Chemotherapy; Older women; Ovarian cancer; Patterns of care

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER REGISTRY; CANCER STAGING; COMORBIDITY; CYSTADENOMA; CYTOREDUCTIVE SURGERY; FEMALE; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; POPULATION RESEARCH; PRIORITY JOURNAL; THERAPY DELAY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUIDELINE ADHERENCE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; REGISTRIES;

EID: 84876296625     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.02.007     Document Type: Article

References (42)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 Cancer J Clin 60 5 2010 277 300
2. S.S. Buys, E. Partridge, and A. Black Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial JAMA 305 22 2011 2295 2303
3. K. Aabo, M. Adams, and P. Adnitt Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group Br J Cancer 78 11 1998 1479 1487
4. A. du Bois, M. Quinn, and T. Thigpen 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 Suppl. 8 2005 viii7 viii12
5. O. Metzger-Filho, C. Moulin, and V. D'Hondt First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions Curr Opin Oncol 22 5 2010 513 520
6. B.A. Winter-Roach, H.C. Kitchener, and T.A. Lawrie Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer Cochrane Database Syst Rev 3 2012 CD004706
7. V. Sundararajan, D. Hershman, and V.R. Grann Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study J Clin Oncol 20 1 2002 173 178
8. D. Hershman, A.T. Fleischauer, and J.S. Jacobson Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study Gynecol Oncol 92 1 2004 293 299
9. C.C. Earle, D. Schrag, and B.A. Neville Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients J Natl Cancer Inst 98 3 2006 172 180
10. K.M. Fairfield, F.L. Lucas, and C.C. Earle Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the Medicare population Cancer 116 20 2010 4840 4848
11. K.M. Fairfield, K. Murray, and F.L. Lucas Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer J Clin Oncol 29 29 2011 3921 3926
12. M.M. Thrall, H.J. Gray, and R.G. Symons Trends in treatment of advanced epithelial ovarian cancer in the Medicare population Gynecol Oncol 122 1 2011 100 106
13. M. Grossi, M.A. Quinn, and V.J. Thursfield Ovarian cancer: patterns of care in Victoria during 1993-1995 Med J Aust 177 1 2002 11 16
14. H.A. Maas, R.F. Kruitwagen, and V.E. Lemmens The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study Gynecol Oncol 97 1 2005 104 109
15. T.L. Jorgensen, S. Teiblum, and M. Paludan Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients Gynecol Oncol 127 2 2012 367 374
16. Australian Cancer Network, National Breast Cancer Centre Clinical practice guidelines for the management of women with epithelial ovarian cancer 2004 National Breast Cancer Centre Camperdown, NSW
17. AIHW Rural, regional and remote health: a guide to remoteness classification 2004 Australian Institute of Health and Welfare Canberra Cat. No. PHE 53
18. D. Trewin Information paper: census of population and housing Socio-economic indexes for areas, Australia 2001 Australian Bureau of Statistics 2003 [ABS Cat No. 2039.0]
19. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 5 1987 373 383
20. National Comprehensive Cancer Network guidelines - ovarian cancer version 3 http://www.nccn.org/professionals/physician-gls/f-guidelines.asp 2012 [accessed 16th July 2012]
21. N. Colombo, M. Peiretti, and G. Parma Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v23 v30
22. W.P. Tew, J. Java, and D. Chi Treatment outcomes for older women with advanced ovarian cancer: results from a phase III clinical trial (GOG182) J Clin Oncol 28 5-Suppl. 2010 [abstract 5030]
23. O. Tredan, J.F. Geay, and S. Touzet Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens Ann Oncol 18 2 2007 256 262
24. GCIG: Gynecologic Cancer Intergroup Update on GCIG trials for epithelial ovarian cancer available at http://www.gcig.igcs.org/Spring2012/2012-june- ovarian-report.pdf 2012 [accessed September 17th 2012]
25. F.A. Tavassoli, and P. Devilee World Health Organization classification of tumours Pathology and genetics of tumours of the breast and female genital organs 2003 IARC Press Lyon
26. A. Bamias, T. Psaltopoulou, and M. Sotiropoulou Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy Cancer 116 6 2010 1462 1468
27. S. Pignata, G. Ferrandina, and G. Scarfone Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study BMC Cancer 8 2008 252
28. V. Hess, R. A'Hern, and N. Nasiri Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment J Clin Oncol 22 6 2004 1040 1044
29. W.C. Wood, D.R. Budman, and A.H. Korzun Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N Engl J Med 330 18 1994 1253 1259
30. G. Bonadonna, P. Valagussa, and A. Moliterni Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 14 1995 901 906
31. C.I. Nagel, F.J. Backes, and E.M. Hade Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer Gynecol Oncol 124 2 2012 221 224
32. J. Wright, T. Doan, and R. McBride Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival Br J Cancer 98 7 2008 1197 1203
33. K.S. Courneya, R.J. Segal, and J.R. Mackey Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial J Clin Oncol 25 28 2007 4396 4404
34. M.J. Newton, S.C. Hayes, and M. Janda Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study BMC Cancer 11 2011 389
35. D.S. Alberts, C. Marth, and R.D. Alvarez Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival Gynecol Oncol 109 2 2008 174 181
36. M.A. Bookman, M.F. Brady, and W.P. McGuire Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup J Clin Oncol 27 9 2009 1419 1425
37. A. du Bois, J. Herrstedt, and A.C. Hardy-Bessard Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer J Clin Oncol 28 27 2010 4162 4169
38. A.N. Gordon, M. Teneriello, and M.F. Janicek Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer Gynecol Oncol 123 3 2011 479 485
39. P. Hoskins, I. Vergote, and A. Cervantes Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin- paclitaxel vs carboplatin-paclitaxel J Natl Cancer Inst 102 20 2010 1547 1556
40. N. Katsumata, M. Yasuda, and F. Takahashi Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 9698 2009 1331 1338
41. T.J. Perren, A.M. Swart, and J. Pfisterer A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 26 2011 2484 2496
42. S. Pignata, G. Scambia, and G. Ferrandina Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial J Clin Oncol 29 27 2011 3628 3635